[Effectiveness and safety of nadroparin in acute coronary syndrome].
OBJECTIVE
To evaluate the effectiveness and safety of subcutaneous low molecular weight heparin (LMWH) used in acute management of patients with non-ST segment elevation acute coronary syndrome (ACS).


METHODS
A total of 102 patients with non-ST segment elevation ACS were treated for at least 48 hours ( > or =5 times) with subcutaneous nadroparin (1 mg/kg each 12 hours). All 102 patients underwent coronary angiographies (CAG) within 8 hours after LMWH injection, followed by immediate percutaneous coronary intervention (PCI).


RESULTS
Anti-Xa activity at the time of catheterization was (0.62 +/- 0.18) IU/ml, and 90% of the patients had anti-Xa activity > 0.5 IU/ml. No death, myocardial infarction relapse or emergent revascularization occurred after PCI. Thrombosis and/or embolism occurred in 2 patients (3.5%) during PCI. Mild hemorrhage was observed in 4 patients (3.9%) of PCI group and in 2 patients (4.4%) in CAG group. No major hemorrhage occurred.


CONCLUSIONS
PCI within 8-12 hours of the last dose after > or =48 hours nadroparin subcutaneous injection seems to be effective and safe.
Lu
Chang-lin
CL
Department of Cardiovascular Center, Beijing Tongren Hospital, Capital University of Medical Sciences, Beijing 100730, China. cardiolucl@yahoo.com.cn
Ni
Ru-yang
RY
Yang
Jin-gang
JG
Hu
Da-yi
DY
Guo
Jing-xuan
JX
D054058:Acute Coronary Syndrome / Q000097:blood / Q000628:therapy*; D000800:Angioplasty, Balloon; D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006801:Humans; D017762:Nadroparin / Q000009:adverse effects / Q000627:therapeutic use*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D017762:Nadroparin